Advertisement
Canada markets open in 1 hour 55 minutes
  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CAD/USD

    0.7294
    -0.0004 (-0.05%)
     
  • CRUDE OIL

    81.70
    +0.13 (+0.16%)
     
  • Bitcoin CAD

    91,025.37
    +1,371.81 (+1.53%)
     
  • CMC Crypto 200

    1,379.69
    -2.97 (-0.21%)
     
  • GOLD FUTURES

    2,352.30
    +5.40 (+0.23%)
     
  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     
  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     
  • NASDAQ futures

    20,038.25
    +119.00 (+0.60%)
     
  • VOLATILITY

    12.60
    +0.12 (+0.96%)
     
  • FTSE

    8,233.31
    +28.20 (+0.34%)
     
  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     
  • CAD/EUR

    0.6796
    +0.0009 (+0.13%)
     

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

VANCOUVER, British Columbia, May 28, 2024--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528369330/en/

Contacts

Inquiries
Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116